Tickers: XTSX:VPT, PINX:VPTDF
Tags: Heathcare, Technology
Toronto, Canada / TheNewswire / February 22, 2018 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company") (TSXV:VPT) is pleased to announce that it has been named to the 2018 TSX Venture 50, a ranking of the top performers on the TSX Venture Exchange over the last year.
"2017 was a historical year for Ventripoint, our employees and shareholders, who have seen the Company increase in market capitalization by 384% and experience share price appreciation of 258%, while trading 206 million shares on the TSX Venture Exchange and 250 million shares on all share exchanges. I would like to take this opportunity to express my gratitude to all of our staff and investors for their continued support and interest in our quest to improve cardiac diagnosis for all," stated Dr. George Adams, CEO of Ventripoint. "We are excited to celebrate this milestone and are working to deliver even more shareholder value in 2018 and beyond."
The TSX Venture 50 ranking is comprised of ten companies from each of the five industry sectors of the TSX Venture Exchange, being: Clean Technology and Life Sciences; Diversified Industries; Mining; Oil & Gas; and Technology. TSX Venture 50 companies are selected based on three equally weighted criteria: market capitalization growth, share price appreciation and trading volume. The TSX Venture Exchange has advised the Company that it will be marketing the TSX Venture 50 rankings across Canada and around the world, and will be posting a video profile about Ventripoint. These materials are available at www.tmxmoney.com.
About Ventripoint Diagnostics Ltd.
Ventripoint's technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR) to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.
For Further Information, Contact:
Dr. George Adams, CEO
T: 519-803-6937
Forward Looking Statements:
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Corporation can give no assurance that they will prove to be correct.
Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management's discussion and analysis that is available on the Corporation's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Copyright (c) 2018 TheNewswire - All rights reserved.
